Abstract:Increased activity of D2 receptors (D2Rs) in the striatum has been linked to the pathophysiology of schizophrenia. To determine directly the behavioral and physiological consequences of increased D2R function in the striatum, we generated mice with reversibly increased levels of D2Rs restricted to the striatum. D2 transgenic mice exhibit selective cognitive impairments in working memory tasks and behavioral flexibility without more general cognitive deficits. The deficit in the working memory task persists eve… Show more
“…Studies have also suggested an increased affinity of D 2 receptors for DA in schizophrenia, which may produce D 2 receptor supersensitivity in the NAc, contributing to psychosis [79]. In an interesting animal model correlate to these studies, transient overexpression of D 2 receptors in the striatum of mice resulted in deficits in prefrontal working memory, resembling some of the features of human schizophrenia [80]. Studies such as these indicate that alterations in DA receptor expression (or function) can result in a dysfunctional reward system.…”
Section: Reviewmentioning
confidence: 99%
“…Kellendonk et al . [80] attempted to model this D 2 receptor elevation in genetically engineered mice, in which they transiently and selectively overexpressed D 2 receptors in the striatum including in the caudate putamen, the NAc, and olfactory tubercle. It was found that 30% of striatal MSNs overexpressed these engineered receptors, thereby elevating the D 2 receptor level to about 15% higher than that of normal mice.…”
This review summarizes evidence of dysregulated reward circuitry function in a range of neurodevelopmental and psychiatric disorders and genetic syndromes. First, the contribution of identifying a core mechanistic process across disparate disorders to disease classification is discussed, followed by a review of the neurobiology of reward circuitry. We next consider preclinical animal models and clinical evidence of reward-pathway dysfunction in a range of disorders, including psychiatric disorders (i.e., substance-use disorders, affective disorders, eating disorders, and obsessive compulsive disorders), neurodevelopmental disorders (i.e., schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum disorders, Tourette’s syndrome, conduct disorder/oppositional defiant disorder), and genetic syndromes (i.e., Fragile X syndrome, Prader–Willi syndrome, Williams syndrome, Angelman syndrome, and Rett syndrome). We also provide brief overviews of effective psychopharmacologic agents that have an effect on the dopamine system in these disorders. This review concludes with methodological considerations for future research designed to more clearly probe reward-circuitry dysfunction, with the ultimate goal of improved intervention strategies.
“…Studies have also suggested an increased affinity of D 2 receptors for DA in schizophrenia, which may produce D 2 receptor supersensitivity in the NAc, contributing to psychosis [79]. In an interesting animal model correlate to these studies, transient overexpression of D 2 receptors in the striatum of mice resulted in deficits in prefrontal working memory, resembling some of the features of human schizophrenia [80]. Studies such as these indicate that alterations in DA receptor expression (or function) can result in a dysfunctional reward system.…”
Section: Reviewmentioning
confidence: 99%
“…Kellendonk et al . [80] attempted to model this D 2 receptor elevation in genetically engineered mice, in which they transiently and selectively overexpressed D 2 receptors in the striatum including in the caudate putamen, the NAc, and olfactory tubercle. It was found that 30% of striatal MSNs overexpressed these engineered receptors, thereby elevating the D 2 receptor level to about 15% higher than that of normal mice.…”
This review summarizes evidence of dysregulated reward circuitry function in a range of neurodevelopmental and psychiatric disorders and genetic syndromes. First, the contribution of identifying a core mechanistic process across disparate disorders to disease classification is discussed, followed by a review of the neurobiology of reward circuitry. We next consider preclinical animal models and clinical evidence of reward-pathway dysfunction in a range of disorders, including psychiatric disorders (i.e., substance-use disorders, affective disorders, eating disorders, and obsessive compulsive disorders), neurodevelopmental disorders (i.e., schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum disorders, Tourette’s syndrome, conduct disorder/oppositional defiant disorder), and genetic syndromes (i.e., Fragile X syndrome, Prader–Willi syndrome, Williams syndrome, Angelman syndrome, and Rett syndrome). We also provide brief overviews of effective psychopharmacologic agents that have an effect on the dopamine system in these disorders. This review concludes with methodological considerations for future research designed to more clearly probe reward-circuitry dysfunction, with the ultimate goal of improved intervention strategies.
“…The PFC receives key ascending dopaminergic inputs from the midbrain and other subcortical areas (Kellendonk et al., 2006; Tekin & Cummings, 2002), and emerging evidence suggests the existence of an optimal level of dopamine needed for efficient PFC functioning (Goldman‐Rakic, Muly, & Williams, 2000). Two genes that have been associated with various psychiatric and neurological disorders and which have attracted attention due to their role in cognitive and emotional processes are the genes encoding for the enzyme catechol‐O‐methyltransferase ( COMT ; Dickinson & Elvevåg, 2009; Scheggia, Sannino, Luisa Scattoni, & Papaleo, 2012; Tunbridge, Harrison, & Weinberger, 2006) and the dopamine receptor D2 ( DRD2 ; Frank & Fossella, 2011; Huertas, Bühler, Echeverry‐Alzate, Giménez, & López‐Moreno, 2012; Kellendonk et al., 2006).…”
Section: Introductionmentioning
confidence: 99%
“…Two genes that have been associated with various psychiatric and neurological disorders and which have attracted attention due to their role in cognitive and emotional processes are the genes encoding for the enzyme catechol‐O‐methyltransferase ( COMT ; Dickinson & Elvevåg, 2009; Scheggia, Sannino, Luisa Scattoni, & Papaleo, 2012; Tunbridge, Harrison, & Weinberger, 2006) and the dopamine receptor D2 ( DRD2 ; Frank & Fossella, 2011; Huertas, Bühler, Echeverry‐Alzate, Giménez, & López‐Moreno, 2012; Kellendonk et al., 2006). COMT is responsible for breaking down ~50–60% of dopamine produced in the frontal cortex (Yavich, Forsberg, Karayiorgou, Gogos, & Männistö, 2007).…”
Section: Introductionmentioning
confidence: 99%
“…D2 receptor availability in the caudate has been associated with performance on executive function tests requiring mental flexibility, abstraction, response inhibition and attention in healthy individuals (Volkow et al., 1998) and D2 receptor occupancy has been associated with vigilance and neurocognitive function in schizophrenia patients (Sakurai et al., 2012), whereas the blockade of D2 receptors by risperidone correlates with attentional deficits in schizophrenia (Uchida et al., 2009). Animal studies have shown that mutant mice lacking D2 receptors exhibit impaired spatial working memory and attentional abilities (Glickstein, DeSteno, Hof, & Schmauss, 2005; Glickstein, Hof, & Schmauss, 2002) and over‐expression of D2 receptors in striatum has similarly been associated with impaired working memory performance in mice (Kellendonk et al., 2006). The C957T (rs6277) polymorphism in the D2 receptor has recently gained interest due to its proposed role in the development of schizophrenia.…”
IntroductionPrevious research has indicated that variation in genes encoding catechol‐O‐methyltransferase (COMT) and dopamine receptor D2 (DRD2) may influence cognitive function and that this may confer vulnerability to the development of mental health disorders such as schizophrenia. However, increasing evidence suggests environmental factors such as early life stress may interact with genetic variants in affecting these cognitive outcomes. This study investigated the effect of COMT Val158Met and DRD2 C957T polymorphisms on executive function and the impact of early life stress in healthy adults.MethodsOne hundred and twenty‐two healthy adult males (mean age 35.2 years, range 21–63) were enrolled in the study. Cognitive function was assessed using Cambridge Neuropsychological Test Automated Battery and early life stress was assessed using the Childhood Traumatic Events Scale (Pennebaker & Susman, 1988).Results
DRD2 C957T was significantly associated with executive function, with CC homozygotes having significantly reduced performance in spatial working memory and spatial planning. A significant genotype–trauma interaction was found in Rapid Visual Information Processing test, a measure of sustained attention, with CC carriers who had experienced early life stress exhibiting impaired performance compared to the CC carriers without early life stressful experiences. There were no significant findings for COMT Val158Met.ConclusionsThis study supports previous findings that DRD2 C957T significantly affects performance on executive function related tasks in healthy individuals and shows for the first time that some of these effects may be mediated through the impact of childhood traumatic events. Future work should aim to clarify further the effect of stress on neuronal systems that are known to be vulnerable in mental health disorders and more specifically what the impact of this might be on cognitive function.
These findings suggest that schizophrenia is associated with elevated dopamine function in associative regions of the striatum. Because the precommissural dorsal caudate processes information from the dorsolateral prefrontal cortex, this observation also suggests that elevated subcortical dopamine function might adversely affect performance of the dorsolateral prefrontal cortex in schizophrenia. On the other hand, the absence of a group difference in the limbic striatum brings into question the therapeutic relevance of the mesolimbic selectivity of second-generation antipsychotic drugs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.